NCT02975674

Evaluation of MT-12 Implant Survival and Marginal Bone Loss

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Universidad de Granada · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The trial is designed as a consecutive enrollment prospective one-center study. A minimum of 30 patients will be included in the study. At implant installation, the patient will be randomized to receive one of the two types of implants (Control: internal hexagon connection implants (CON.INT); Test: Morse taper connection implants (MT-12)). Samples of peri-implant crevicular fluid (PICF) and intrasulcular plaque will be collected at -21 (second-stage surgery), -14 (impressions), 0 (Baseline: prosthesis delivery), 7 days and 1, 3, 6, 12 months. Prosthesis will be fabricated and delivered as usual, i.e., approximately two weeks after the impressions are taken.

Conditions

• Jaw, Edentulous, Partially

Interventions

Type	Name	Description
DEVICE	MT-12 dental implant	Placement of the MT-12 dental implant with Morse taper implant-abutment connection
DEVICE	CON.INT dental implant	Placement of the CON.INT dental implant with internal hexagon implant-abutment connection

Timeline

• Start date: 2016-11-01
• Primary completion: 2021-02-01
• Completion: 2021-02-01
• First posted: 2016-11-29
• Last updated: 2023-05-23

Locations

1 site across 1 country: Spain